JP2015514062A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514062A5 JP2015514062A5 JP2015500673A JP2015500673A JP2015514062A5 JP 2015514062 A5 JP2015514062 A5 JP 2015514062A5 JP 2015500673 A JP2015500673 A JP 2015500673A JP 2015500673 A JP2015500673 A JP 2015500673A JP 2015514062 A5 JP2015514062 A5 JP 2015514062A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- cadherin
- fragment
- secad
- inhibits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 86
- 102000000905 Cadherin Human genes 0.000 claims description 60
- 108050007957 Cadherin Proteins 0.000 claims description 60
- 239000012634 fragment Substances 0.000 claims description 52
- 239000008194 pharmaceutical composition Substances 0.000 claims description 49
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 102000038030 PI3Ks Human genes 0.000 claims description 12
- 108091007960 PI3Ks Proteins 0.000 claims description 12
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 12
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 239000013604 expression vector Substances 0.000 claims description 12
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- 230000019491 signal transduction Effects 0.000 claims description 12
- 102000043136 MAP kinase family Human genes 0.000 claims description 10
- 108091054455 MAP kinase family Proteins 0.000 claims description 10
- 239000012636 effector Substances 0.000 claims description 10
- 102000005962 receptors Human genes 0.000 claims description 10
- 108020003175 receptors Proteins 0.000 claims description 10
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims description 8
- 102000001301 EGF receptor Human genes 0.000 claims description 8
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims description 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 8
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 8
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 8
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 8
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims description 8
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims description 8
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims description 8
- 108091008605 VEGF receptors Proteins 0.000 claims description 8
- 229960000241 vandetanib Drugs 0.000 claims description 8
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 8
- LSFLAQVDISHMNB-UHFFFAOYSA-N 5-(3-phenylmethoxyphenyl)-7-[3-(pyrrolidin-1-ylmethyl)cyclobutyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C2CC(CN3CCCC3)C2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 LSFLAQVDISHMNB-UHFFFAOYSA-N 0.000 claims description 6
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 6
- 229960005395 cetuximab Drugs 0.000 claims description 6
- 229960001972 panitumumab Drugs 0.000 claims description 6
- 229960000575 trastuzumab Drugs 0.000 claims description 6
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims description 6
- 229960002833 aflibercept Drugs 0.000 claims description 5
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims description 4
- 108091008815 Eph receptors Proteins 0.000 claims description 4
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 claims description 4
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims description 4
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 4
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims description 4
- 108091008553 MuSK receptors Proteins 0.000 claims description 4
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 4
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 claims description 4
- 108091008551 RET receptors Proteins 0.000 claims description 4
- 101710204410 Scaffold protein Proteins 0.000 claims description 4
- 108010017622 Somatomedin Receptors Proteins 0.000 claims description 4
- 102000004584 Somatomedin Receptors Human genes 0.000 claims description 4
- 102000005450 TIE receptors Human genes 0.000 claims description 4
- 108010006830 TIE receptors Proteins 0.000 claims description 4
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims description 4
- 230000031146 intracellular signal transduction Effects 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- -1 AG1024 Chemical compound 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 2
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 2
- 108010081667 aflibercept Proteins 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 210000004994 reproductive system Anatomy 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 229960002760 ziv-aflibercept Drugs 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims 24
- 230000037361 pathway Effects 0.000 claims 6
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 4
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 4
- 230000004068 intracellular signaling Effects 0.000 claims 4
- 229940126638 Akt inhibitor Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 230000007717 exclusion Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims 2
- 239000003197 protein kinase B inhibitor Substances 0.000 claims 2
- 230000026683 transduction Effects 0.000 claims 2
- 238000010361 transduction Methods 0.000 claims 2
- QDITZBLZQQZVEE-YBEGLDIGSA-N (5z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=C(N=CC=C2C=3C=CN=CC=3)C2=C1 QDITZBLZQQZVEE-YBEGLDIGSA-N 0.000 claims 1
- KVLFRAWTRWDEDF-IRXDYDNUSA-N AZD-8055 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 claims 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims 1
- 239000012824 ERK inhibitor Substances 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 229940124647 MEK inhibitor Drugs 0.000 claims 1
- 239000012828 PI3K inhibitor Substances 0.000 claims 1
- 239000012823 PI3K/mTOR inhibitor Substances 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 229950003628 buparlisib Drugs 0.000 claims 1
- 229960002271 cobimetinib Drugs 0.000 claims 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 claims 1
- 229950006418 dactolisib Drugs 0.000 claims 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 claims 1
- 229950010632 perifosine Drugs 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 239000013543 active substance Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 3
- 239000000092 prognostic biomarker Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000025188 carcinoma of pharynx Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000005001 male reproductive tract Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261611390P | 2012-03-15 | 2012-03-15 | |
| US61/611,390 | 2012-03-15 | ||
| US201261736475P | 2012-12-12 | 2012-12-12 | |
| US61/736,475 | 2012-12-12 | ||
| PCT/US2013/032656 WO2013138790A1 (en) | 2012-03-15 | 2013-03-15 | Combination therapies including inhibitors of the extracellular domain of e-cadherin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015514062A JP2015514062A (ja) | 2015-05-18 |
| JP2015514062A5 true JP2015514062A5 (cg-RX-API-DMAC7.html) | 2016-05-12 |
Family
ID=49161879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500673A Pending JP2015514062A (ja) | 2012-03-15 | 2013-03-15 | Ｅ−カドヘリンの細胞外ドメインの阻害剤を含む併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20150037354A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2844270A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015514062A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140138956A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104519899A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2867456A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2014141114A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013138790A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014043633A1 (en) * | 2012-09-17 | 2014-03-20 | Agios Pharmaceuticals, Inc. | Use of e-cadherin and vimentin for selection of treatment responsive patients |
| KR20150085078A (ko) | 2012-11-21 | 2015-07-22 | 아지오스 파마슈티컬스 아이엔씨. | 글루타마제 억제제 및 사용 방법 |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| CA2943339A1 (en) | 2014-03-21 | 2015-09-24 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| DK3170005T3 (da) * | 2014-07-18 | 2019-07-08 | Sanofi Sa | Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer |
| CN111208283B (zh) * | 2018-11-21 | 2023-09-26 | 中国科学院分子细胞科学卓越创新中心 | 增效的肿瘤抑制组合物及其应用 |
| CN115040695B (zh) * | 2021-03-09 | 2023-10-13 | 南开大学 | 一种基于VE-cad-Fc/N-cad-Fc的融合蛋白活性界面的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT414097B (de) * | 2004-06-25 | 2006-09-15 | Petzelbauer Peter Dr | Pharmazeutische zubereitung zur behandlung von schock |
| CA2760642A1 (en) * | 2009-05-01 | 2010-11-04 | The University Of Tokyo | Anti-cadherin antibody |
| CN103582494A (zh) * | 2010-10-27 | 2014-02-12 | 纽约州立大学研究基金会 | 靶向e-钙粘着蛋白的可溶性细胞外结构域的组合物和用于癌症治疗的有关方法 |
-
2013
- 2013-03-15 US US14/385,351 patent/US20150037354A1/en not_active Abandoned
- 2013-03-15 JP JP2015500673A patent/JP2015514062A/ja active Pending
- 2013-03-15 CA CA2867456A patent/CA2867456A1/en not_active Abandoned
- 2013-03-15 CN CN201380024208.0A patent/CN104519899A/zh active Pending
- 2013-03-15 RU RU2014141114A patent/RU2014141114A/ru not_active Application Discontinuation
- 2013-03-15 EP EP13760736.2A patent/EP2844270A4/en not_active Withdrawn
- 2013-03-15 KR KR1020147028934A patent/KR20140138956A/ko not_active Withdrawn
- 2013-03-15 WO PCT/US2013/032656 patent/WO2013138790A1/en not_active Ceased
-
2018
- 2018-01-29 US US15/882,513 patent/US20190008957A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514062A5 (cg-RX-API-DMAC7.html) | ||
| US10966985B2 (en) | Macrocyclic compounds as ROS1 kinase inhibitors | |
| Muñoz et al. | The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists | |
| Qin et al. | CTHRC1 promotes wound repair by increasing M2 macrophages via regulating the TGF-β and notch pathways | |
| JP4384852B2 (ja) | 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置 | |
| RU2013123792A (ru) | Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний | |
| RU2014141114A (ru) | Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина | |
| JP2013083665A (ja) | 黒色腫における治療応答のための早期指標としての黒色腫阻害性活性（ｍｉａ）タンパク質の使用 | |
| WO2010120592A1 (en) | Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors | |
| CN105873950A (zh) | 用于治疗和诊断癌症的抗s100a7抗体 | |
| US20220056123A1 (en) | Use of il-1beta binding antibodies | |
| CN109709335B (zh) | 热休克蛋白hspa4在肿瘤转移预测、预后评估和治疗中的应用 | |
| TWI842966B (zh) | 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途 | |
| TWI517852B (zh) | 微小ＲＮＡ ｍｉＲ－１９９ａ－５ｐ之用途 | |
| WO2016065877A1 (zh) | Cd166作为肝癌诊断血清标志物的应用及其试剂盒 | |
| CN115175678B (zh) | 使用btk抑制剂及其组合治疗dlbcl的方法 | |
| CN119997973A (zh) | 使用间充质上皮转化因子（met）靶向剂治疗非小细胞肺癌的方法 | |
| Sachdev et al. | 506 Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer | |
| JPWO2020243442A5 (cg-RX-API-DMAC7.html) | ||
| Smithberger | Kinome-Guided Development of Precision-Targeted Therapeutics for Glioblastoma | |
| CN105879033A (zh) | GnRH II型拮抗剂在抑制孕激素耐药子宫内膜癌细胞增殖中的应用 | |
| CN118354772A (zh) | 治疗头颈癌的方法 | |
| AU2024210360A1 (en) | Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy | |
| WO2024254266A1 (en) | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer | |
| Choucair | Crosstalk between IGF-1 and estrogen receptor non-genomic signaling pathway in breast cancer |